Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US ...
FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment. As health systems continue expanding the use of ...
FDA approves Poherdy, the first interchangeable biosimilar for pertuzumab (Perjeta), enhancing competition in HER2-positive breast cancer treatment. The FDA has granted approval to Poherdy (pertuzumab ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback